Welcome to our dedicated page for Icad news (Ticker: ICAD), a resource for investors and traders seeking the latest updates and insights on Icad stock.
This page provides a historical news archive for iCAD, Inc. (formerly NASDAQ: ICAD), a company that described itself as a global leader in clinically proven AI-powered breast health and cancer detection solutions. Before becoming a wholly owned subsidiary of RadNet, Inc., iCAD regularly issued news releases detailing its product developments, clinical research, commercial partnerships, and financial performance.
Readers can review announcements about the ProFound Breast Health Suite, which iCAD characterized as an industry-leading AI-powered mammography analysis platform for breast cancer detection, density assessment, and risk evaluation. News items include updates on FDA clearances for ProFound Detection versions, the introduction of ProFound Cloud as a scalable SaaS platform, and collaborations that integrated iCAD’s AI technology into radiology information systems, PACS platforms, and cloud-based precision imaging networks.
The archive also covers financial news, such as quarterly and annual results, trends in annual recurring revenue associated with the company’s transition to a subscription and cloud-based model, and commentary from management on operating performance. Additional releases highlight clinical abstracts and presentations at major conferences, where research collaborators evaluated iCAD’s AI tools for early detection, risk prediction, and breast arterial calcification assessment across diverse populations.
Because iCAD completed a merger with RadNet in July 2025 and its common stock ceased trading independently, the ICAD news feed now serves as a record of historical communications from iCAD’s time as a standalone public company. Investors, clinicians, and researchers can use this archive to understand how the company described its technology, strategy, and clinical evidence prior to its integration into RadNet’s diagnostic imaging and digital health portfolio.
iCAD (NASDAQ:ICAD), a leader in medical technology, will present at the Spring Into Action - Best Ideas Virtual Investor Conference from May 16-20, 2022. Stacey Stevens, President and CEO, is scheduled to speak on May 17 from 11:30 to 11:55 a.m. EST. The presentation will be available for live webcast and replay. Investors interested in one-on-one meetings or further details can email angie.wright@issuerdirect.com. For registration, visit here.
iCAD, a leader in cancer detection technology, reported its Q1 2022 results, revealing a 13.0% decline in total revenue to $7.5 million, attributed to decreases in both product and service revenues. The company recorded a GAAP net loss of $3.5 million, compared to a loss of $1.6 million in Q1 2021. Despite a 70.6% gross profit margin, operating expenses rose by 12.9%. Notably, iCAD secured an enterprise agreement for ProFound AI and is advancing clinical research, with promising developments in its GLIOX trial.
iCAD recently highlighted its ProFound AI technology as the leading solution in a competitive trial conducted by Wake Radiology, which operates 14 imaging centers in North Carolina. The upcoming webinar, part of iCAD's series 'ProFound Insights, ProFound Impact,' will discuss the advantages of ProFound AI and its flexibility in reading mammograms across various systems. The event will feature experts from Wake Radiology and aims to showcase the effectiveness of iCAD's solutions in enhancing breast imaging practices.
iCAD, Inc. (NASDAQ: ICAD), a leader in cancer detection and therapy solutions, announced it will release its financial results for Q1 2022 on May 11, 2022, after market close. The company will also host a conference call at 4:30 PM ET the same day, where details on financial performance will be discussed. Interested parties can join via the provided domestic and international numbers or through a webcast. The upcoming financial results are anticipated to provide insights into the company’s growth and strategic direction.
iCAD reports strong commercial momentum for its ProFound AI breast health solutions, outperforming competitors in clinical performance and workflow efficiency. Key clients, including Wake Radiology and Kettering Health, have transitioned to ProFound AI, citing significant improvements in accuracy and efficiency for mammography readings. The AI integration has been praised for reducing false positives and enhancing patient care. Ongoing improvements to the technology have further solidified customer satisfaction and market positioning.
iCAD (NASDAQ: ICAD) anticipates a preliminary revenue of $7.5 million for Q1 2022, reflecting ongoing growth in the medical technology sector focused on cancer detection and therapy solutions. The company has appointed Timothy Norris Irish as the new Chairman of the Board, succeeding Michael Klein. Irish brings extensive experience from the healthcare sector. Furthermore, CFO Charles Carter will be leaving the position, with an interim CFO to be announced soon. iCAD remains optimistic about its commercial infrastructure and future prospects.
iCAD announced the launch of a new webinar series called ProFound Insights, ProFound Impact, starting with an event titled “Why Kettering Health Traded out Previous AI Software for ProFound AI®”. The first session is scheduled for April 27, 2022, featuring experts from Kettering Health, an enterprise breast care provider in southwest Ohio. The event will showcase customer success stories, emphasizing the effectiveness of ProFound AI in enhancing reading efficiency and patient care, as noted by Kettering's Director and Medical Director.
iCAD announced positive developments regarding its Xoft electronic brachytherapy (eBx) technology, particularly in the international multi-center GLIOX trial.
Clinicians across Spain report successful treatments using the Xoft System for recurrent glioblastoma and various cancers, showcasing its versatility.
The system, FDA-cleared and CE marked, offers efficient treatment with minimal side effects, potentially replacing weeks of traditional therapy. Preliminary data indicates promising outcomes, with extended survival rates for patients treated with Xoft compared to the control group.
iCAD, Inc. (NASDAQ: ICAD) showcased its innovative Breast AI solutions at the HIMSS Global Health Conference in Orlando, FL, from March 14-18, 2022. The company highlights the capabilities of ProFound AI® for Digital Breast Tomosynthesis, which enhances reading accuracy and reduces reading time significantly. iCAD's suite includes tools for cancer detection, breast density assessment, and risk evaluation, all designed to improve workflow and interoperability in healthcare systems. The technology integrates with NVIDIA AI Enterprise, optimizing IT environments to enhance cancer detection capabilities.
iCAD will showcase its award-winning breast health solutions at the inaugural Pink Paradigm Summit and the NCoBC Annual Conference in Las Vegas from March 11-16, 2022. With innovations like ProFound AI for Digital Breast Tomosynthesis and the PowerLook® Breast Density Assessment, iCAD's technology aims to enhance breast cancer detection and patient care. Presentation by Mark Traill, MD, will highlight the benefits of AI in breast cancer risk assessment. CEO Stacey Stevens emphasized the significance of these gatherings to connect with clinical leaders and advocates.